Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma

The adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has led to durable tumor regressions in select patients with cancer. However, it remains unknown whether such T cells can be isolated from and used to treat patients with glioblastoma, a cancer that is refractory...

Full description

Saved in:
Bibliographic Details
Main Authors: Steven A Rosenberg, Paul Robbins, Biman Paria, Todd D Prickett, Jared J Gartner, Devikala Gurusamy, Stephanie L Goff, Vid Leko, Gal Cafri, Rami Yossef, Victoria Hill
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002882.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850062474289610752
author Steven A Rosenberg
Paul Robbins
Biman Paria
Todd D Prickett
Jared J Gartner
Devikala Gurusamy
Stephanie L Goff
Vid Leko
Gal Cafri
Rami Yossef
Victoria Hill
author_facet Steven A Rosenberg
Paul Robbins
Biman Paria
Todd D Prickett
Jared J Gartner
Devikala Gurusamy
Stephanie L Goff
Vid Leko
Gal Cafri
Rami Yossef
Victoria Hill
author_sort Steven A Rosenberg
collection DOAJ
description The adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has led to durable tumor regressions in select patients with cancer. However, it remains unknown whether such T cells can be isolated from and used to treat patients with glioblastoma, a cancer that is refractory to currently available therapies. To answer this question, we stimulated patient blood-derived memory T cells in vitro using peptides and minigenes that represented point mutations unique to patients’ tumors (ie, candidate neoantigens) and then tested their ability to specifically recognize these mutations. In a cohort of five patients with glioblastoma, we found that circulating CD4+ memory T cells from one patient recognized a cancer neoantigen harboring a mutation in the EED gene (EEDH189N) that was unique to that patient’s tumor. This finding suggests that neoantigen-reactive T cells could indeed be isolated from patients with glioblastoma, thereby providing a rationale for further efforts to develop neoantigen-directed adoptive T cell therapy for this disease.
format Article
id doaj-art-d996d8bb72c542bf890895b0f8a8b016
institution DOAJ
issn 2051-1426
language English
publishDate 2021-07-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-d996d8bb72c542bf890895b0f8a8b0162025-08-20T02:49:55ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-07-019710.1136/jitc-2021-002882Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastomaSteven A Rosenberg0Paul Robbins1Biman Paria2Todd D Prickett3Jared J Gartner4Devikala Gurusamy5Stephanie L Goff6Vid Leko7Gal Cafri8Rami Yossef9Victoria Hill10National Cancer Institute, Bethesda, MD, USASurgery Branch, National Cancer Institute, Bethesda, Maryland, USAProgram Coordination and Referral Branch, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, National Cancer Institute, Bethesda, Maryland, USASheba Medical Center, Ramat Gan, IsraelSurgery Branch, National Cancer Institute, Bethesda, Maryland, USASurgery Branch, National Cancer Institute, Bethesda, Maryland, USAThe adoptive transfer of naturally occurring T cells that recognize cancer neoantigens has led to durable tumor regressions in select patients with cancer. However, it remains unknown whether such T cells can be isolated from and used to treat patients with glioblastoma, a cancer that is refractory to currently available therapies. To answer this question, we stimulated patient blood-derived memory T cells in vitro using peptides and minigenes that represented point mutations unique to patients’ tumors (ie, candidate neoantigens) and then tested their ability to specifically recognize these mutations. In a cohort of five patients with glioblastoma, we found that circulating CD4+ memory T cells from one patient recognized a cancer neoantigen harboring a mutation in the EED gene (EEDH189N) that was unique to that patient’s tumor. This finding suggests that neoantigen-reactive T cells could indeed be isolated from patients with glioblastoma, thereby providing a rationale for further efforts to develop neoantigen-directed adoptive T cell therapy for this disease.https://jitc.bmj.com/content/9/7/e002882.full
spellingShingle Steven A Rosenberg
Paul Robbins
Biman Paria
Todd D Prickett
Jared J Gartner
Devikala Gurusamy
Stephanie L Goff
Vid Leko
Gal Cafri
Rami Yossef
Victoria Hill
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
Journal for ImmunoTherapy of Cancer
title Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
title_full Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
title_fullStr Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
title_full_unstemmed Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
title_short Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
title_sort identification of neoantigen reactive t lymphocytes in the peripheral blood of a patient with glioblastoma
url https://jitc.bmj.com/content/9/7/e002882.full
work_keys_str_mv AT stevenarosenberg identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT paulrobbins identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT bimanparia identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT todddprickett identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT jaredjgartner identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT devikalagurusamy identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT stephanielgoff identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT vidleko identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT galcafri identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT ramiyossef identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma
AT victoriahill identificationofneoantigenreactivetlymphocytesintheperipheralbloodofapatientwithglioblastoma